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Bacille Calmette-Gue´rin (BCG) vaccine exerts nonspecific immunostimulatory effects and may therefore represent a novel
therapeutic option to treat sepsis-induced immunoparalysis. We investigated whether BCG vaccination modulates the systemic
innate immune response in humans in vivo during experimental endotoxemia.We used inactivated gamma-irradiated BCGvaccine
because of the potential risk of disseminated disease with the live vaccine in immunoparalyzed patients. In a randomized double-
blind placebo-controlled study, healthy male volunteers were vaccinated with gamma-irradiated BCG (𝑛 = 10) or placebo (𝑛 = 10)
and received 1 ng/kg lipopolysaccharide (LPS) intravenously on day 5 after vaccination to assess the in vivo immune response.
Peripheral blood mononuclear cells were stimulated with various related and unrelated pathogens 5, 8 to 10, and 25 to 35 days
after vaccination to assess ex vivo immune responses. BCG vaccination resulted in a scar in 90% of vaccinated subjects. LPS
administration elicited a profound systemic immune response, characterized by increased levels of pro- and anti-inflammatory
cytokines, hemodynamic changes, and flu-like symptoms. However, BCG modulated neither this in vivo immune response,
nor ex vivo leukocyte responses at any time point. In conclusion, gamma-irradiated BCG is unlikely to represent an effective
treatment option to restore immunocompetence in patients with sepsis-induced immunoparalysis. This trial is registered with
NCT02085590.
1. Introduction
Sepsis is a clinical condition that represents a major medical
challenge due to its high mortality rate. Related to this, it is
a major clinical challenge also because it may be difficult to
diagnose in due time and difficult to treat. Previous adjunc-
tive therapeutic strategies, aiming to treat sepsis by inhibition
of proinflammatory mediators, have failed, likely related to
the recent insight that the majority of septic patients do not
succumb to the initial proinflammatory “hit” but die at a later
time point in a pronounced immunosuppressive state [1–
3]. This so-called “sepsis-induced immunoparalysis” results
from counterregulatory anti-inflammatory pathways that are
activated simultaneously with proinflammatory mechanisms
[2–4]. This renders patients unable to clear the initial infec-
tion and increases vulnerability to secondary infections [2, 3,
5]. As a consequence, reconstitution of immunocompetence
is emerging as a new and promising therapeutic target to
improve outcome in sepsis patients [2, 3, 6, 7].
Bacille Calmette-Gue´rin (BCG) is the most widely used
vaccine worldwide. In addition to protection against tubercu-
losis [8], both observational studies and randomized clinical
trials have shown that BCG vaccination is associated with
beneficial effects on other infectious diseases as well. In this
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Figure 1: Experimental design. BCG: Bacille Calmette-Gue´rin; LPS: lipopolysaccharide.
regard, early administration of BCG vaccination leads to
strongly reduced infant mortality, mainly as a result of lower
incidence of neonatal sepsis, respiratory infection, and fever
[9–15]. These nonspecific effects of BCG are suggested to
be mediated by two mechanisms: potentiation of adaptive
immune responses against unrelated pathogens, the so-called
“heterologous immunity” [16], and epigenetic functional
reprogramming of innate immune cells to an enhanced phe-
notype, a process described as “trained immunity” [17–20].
The latter process is characterized by enhanced production
of proinflammatory cytokines by monocytes that have been
previously primed by BCG and is apparent upon stimulation
with either specific or unrelated pathogens [17, 21]. In line
with this, mononuclear cells isolated from healthy volunteers
and stimulated with unrelated pathogens show enhanced
innate immune responses after BCG vaccination [17], and
some of these effects even persist for up to one year [21].
These effects largely rely on innate immune cells, as BCG
vaccination enhances resistance against Candida infection
and increased lipopolysaccharide- (LPS-) induced cytokine
production in splenocytes of mice lacking T- and B-cells [17].
Considering its potentiating effects on host defense, BCG
could represent a therapeutic option to prevent or treat
sepsis-induced immunoparalysis. Nevertheless, as patients
with sepsis have an increased susceptibility to secondary
infections, vaccination with live BCGmay be associated with
unwarranted risks for dissemination [22]. As recent data
showed that gamma-irradiated BCG has similar potentiating
effects on trained immunity in vitro (Arts et al., submitted)
but does not present any risk for infection, this inactivated
form of BCG represents a clinically relevant alternative in
these patients. However, the effects of BCG vaccination on
the immune response in humans have hitherto only been
shown ex vivo [17, 21]. It has yet to be established whether
these findings can be extrapolated to the human in vivo
situation, because ex vivo data might not always reflect
in vivo responses [23, 24]. The human endotoxemia model,
in which a low dose of LPS is administered to healthy
volunteers, represents a uniquemodel to studymodulation of
the systemic inflammation in humans in vivo in a safe, highly
standardized, and reproducible manner [25].
The aim of the present study was to investigate the
effects of vaccination with gamma-irradiated BCG on the
systemic innate immune response in adult males in vivo
during experimental endotoxemia.
2. Methods
2.1. Subjects. After approval from the Arnhem-Nijmegen
Ethics Committee, 20 healthy nonsmoking male volunteers
gave written informed consent to participate in this study
that was registered at ClinicalTrials.gov as NCT02085590.
Subjects were screened before the start of the experiment
and had a normal physical examination, electrocardiography,
and routine laboratory values. Exclusion criteria were febrile
illness during the 2 weeks before start of the study, prior
BCG vaccination, any vaccination other than BCG within 3
months before start of the study, and a tuberculin skin test
within 1 year prior to the start of the study. Throughout the
study period, subjects were not allowed to take any drugs,
including acetaminophen, and were asked to refrain from
alcohol and caffeine 24 hours and from food 12 hours before
the start of the endotoxemia experiment. All study proce-
dures were conducted in accordance with the declaration
of Helsinki including current revisions and Good Clinical
Practice guidelines.
2.2. Study Design and Procedures. We performed a random-
ized double-blind placebo-controlled study.The study design
is schematically depicted in Figure 1. For reasons detailed
in the Introduction, gamma-irradiated (and therefore inac-
tivated) BCG vaccine was used in this study. Irradiated
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BCG was cultured for 6 weeks using Mycobacteria Growth
Indicator Tubes according to Dutch national guidelines to
confirm inactivation, and no growth was observed. Subjects
were randomly assigned to receive either 0.075mg (0.1mL)
gamma-irradiated BCG vaccine intracutaneously (BCG vac-
cine SSI; Statens Serum Institut, gamma-irradiation (25–
30 kGy) performed by Synergy Health Ede, Netherlands;
𝑛 = 10) or 0.1mL placebo (BCG-reconstitution fluid:
diluted Sauton 1+3; Statens Serum Institut; 𝑛 = 10) in a
double-blind fashion. Five days after vaccination, all subjects
received an intravenous injection of LPS (lipopolysaccharide
derived from Escherichia coliO:113, Clinical Center Reference
Endotoxin, National Institutes of Health (NIH), Bethesda,
MD), 1 ng/kg. Endotoxemia experiments were conducted as
described previously [24]. Heart rate (three-lead electro-
cardiogram), blood pressure, respiratory rate, and oxygen
saturation (pulse oximetry) datawere recorded from aPhilips
MP50 patient monitor every 30 seconds by a custom in-
house-developeddata recording system. LPS-inducedflu-like
symptoms (headache, nausea, shivering, muscle, and back
pain) were scored every 30min on a six-point Likert scale (0
= no symptoms, 5 = worst ever experienced), resulting in a
total score of 0–25 points. After the endotoxemia experiment,
additional blood samples were drawn on days 8–10 and
days 25–30 after vaccination. During the last visit, BCG scar
formation was measured by an independent research nurse
(to maintain blinding) using a centimeter ruler.
2.3. Cytokine Measurements. To analyze plasma cytokines,
ethylenediaminetetraacetic acid (EDTA) anticoagulated
blood was centrifuged at 2,000×g at 4∘C for 10 minutes
immediately after withdrawal, and plasma was stored at
−80∘C until analysis. Concentrations of TNF-𝛼, IL-6, IL-8,
IL-10, IL-1𝛽, IL-1 receptor antagonist (IL-1ra), MCP-1, and
IFN-𝛾 were measured in plasma batchwise using a Luminex
assay according to themanufacturer’s instructions (Milliplex;
Millipore, Billerica, MA, USA).
2.4. Leukocyte Counts and Differentiation. Analysis of leuko-
cyte counts and differentiation was performed in EDTA anti-
coagulated blood using routine analysis methods also used
for patient samples (flow cytometric analysis on a SysmexXE-
5000).
2.5. Peripheral Mononuclear Cell Stimulation Assays. The
mononuclear cell fraction was isolated by density centrifuga-
tion of EDTA anticoagulated blood, diluted 1 : 1 in pyrogen-
free saline, over Ficoll-Paque (Pharmacia Biotech, Uppsala,
Sweden). Isolated cells were washed twice in saline and resus-
pended in culture medium (RPMI, Invitrogen, Carlsbad,
California, USA) supplemented with 10 𝜇g/mL gentamicin,
10mM L-glutamine, and 10mM pyruvate. Cell counts were
performed in a Coulter counter (Coulter Electronics). A total
of 5 × 105 mononuclear cells in 100 𝜇L were added to round-
bottomed 96-well plates (Greiner) with RPMI, sonicated
Mycobacterium tuberculosis (MTB) (1 𝜇g/mL end protein
concentration, strain H37Rv), Escherichia coli lipopolysac-
charide (LPS; 1 ng/mL; Sigma-Aldrich, St. Louis, MO, USA),
heat-killed Staphylococcus aureus (1 × 106 microorgan-
isms/mL, clinical isolate), or heat-killed Candida albicans
(1 × 106 microorganisms/mL, strain UC820). After 24 h
(for determination of TNF-𝛼, IL-1𝛽, and IL-6) or 48 h (for
determination of IFN-𝛾 and IL-10) of incubation, plates
were centrifuged and supernatants were stored at −20∘C
until analysis. Cytokines were measured batchwise using
commercially available ELISAs (R&D Systems, MN, USA,
and Sanquin, Amsterdam, Netherlands) according to the
protocols supplied by the manufacturers.
2.6. Calculations and Statistical Analysis. Data are repre-
sented as median and interquartile range or mean and
SEM, based on their distribution (calculated by the Shapiro-
Wilk test). The area under the curve (AUC) of cytokine
levels during experimental endotoxemia, representing an
integrated measure of the cytokine response, was calculated
using time points 0–8 hours after LPS. Comparisons were
made usingMann-Whitney𝑈 tests (nonnormally distributed
data, between-group comparisons) or repeated measures
two-way ANOVA (normally distributed data, where the time
factor represents differences across both groups over time and
the interaction factor represents between-group differences
over time). Ex vivo cytokine data were log-transformed to
obtain a normal distribution. A𝑃 value< 0.05was considered
statistically significant. Calculations and statistical analyses
were performed using Graphpad Prism version 5.0 (Graph-
pad Software, San Diego, CA, USA).
3. Results
3.1. Baseline Characteristics. No differences in baseline char-
acteristics between both groups were present (Table 1).
Gamma-irradiated BCG vaccination resulted in a scar at the
vaccination site in 9 out 10 subjects (median (range) size of 6
(1–9)mm). In the placebo group, 1 subject developed a small
scar (1mm). BCG vaccination did not result in fever or other
clinical symptoms and no serious adverse events occurred
during the trial.
3.2. Hemodynamic Parameters and Symptoms. LPS admin-
istration resulted in a typical increase in heart rate and flu-
like symptoms and a decrease inmean arterial blood pressure
(MAP) in all subjects, with no differences between groups
(Figure 2).
3.3. Plasma Cytokines and Circulating Leukocyte Counts.
BCG vaccination did not result in increased plasma levels
of any of the measured cytokines in the days following
vaccination (Figure 3). As expected, administration of LPS
resulted in a sharp increase in plasma levels of the proinflam-
matory cytokines TNF-𝛼, IL-6, IL-8, and MCP-1, as well as
the anti-inflammatory cytokines IL-10 and IL-1RA (Figure 3).
However, no differences were observed between the BCG
and placebo groups. Similar to previous human endotoxemia
studies [26], plasma levels of IL-1𝛽 and IFN-𝛾 were below
the lower detection limits in the majority of the subjects
at most time points. In some subjects and/or time points,
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Table 1: Baseline characteristics.
Placebo (n = 10) Gamma-irradiated BCG (n = 10) 𝑃 value
Age, y 20.0 (19.0–24.3) 20.5 (19.8–22.0) 0.82
Height, cm 183.0 (178.3–193.0) 183.5 (178.8–189.8) 0.91
Weight, kg 80.8 (70.3–83.5) 78.9 (76.4–93.4) 0.58
BMI, kg/m2 22.7 (21.5–24.7) 24.2 (23.1–25.8) 0.09
Heart rate, bpm 66.0 (59.0–76.3) 70.0 (64.8–82.0) 0.30
MAP, mmHg 97.0 (95.0–103.8) 93.0 (89.5–99.3) 0.14
BCG: Bacille Calmette-Gue´rin; BMI: body mass index; MAP: mean arterial pressure.
Data are represented as median (interquartile range). 𝑃 values calculated using Mann-Whitney 𝑈 tests.
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Figure 2: Blood pressure, heart rate, and symptoms during experimental endotoxemia in subjects vaccinated with gamma-irradiated BCG
or placebo. Data are expressed as mean ± SEM (𝑛 = 10 per group). 𝑃 values calculated using repeated measures two-way analysis of variance
(ANOVA, time and interaction terms). MAP: mean arterial pressure; HR: heart rate; bpm: beats/min.
very low levels (approximately 10 pg/mL) were found, but no
clear patterns over time or differences between groups were
observed.
As described earlier, scar size differed substantially
between BCG-vaccinated subjects, which might represent
vaccination efficacy, and is associated with nonspecific ben-
eficial effects of BCG [27, 28]. Therefore, we stratified
the BCG-vaccinated group according to scar size (≤5mm,
𝑛 = 5; >5mm, 𝑛 = 5). These stratified analyses did
not reveal notable differences in cytokine responses either
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Figure 3: Plasma cytokine concentrations in subjects vaccinated with gamma-irradiated BCG or placebo. In the panels (a–d), median values
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respective cytokines (𝑛 = 10 per group). 𝑃 values calculated using Mann-Whitney 𝑈 tests.
(see Supplementary Figure 1 in the Supplementary Material
available online at http://dx.doi.org/10.1155/2015/261864).
After LPS administration, transient leukocytosis devel-
oped, reaching maximum levels at 𝑇 = 8 hours, with
no differences between groups (mean ± SEM of BCG and
placebo groups, respectively: 10.2±0.7 versus 9.7±0.7×109/L,
𝑃 = 0.62). At the first visit after the endotoxemia day (days
8–10), leukocyte numbers were normalized in both groups
(5.2 ± 0.4 versus 5.7 ± 0.6 × 109/L in the BCG and placebo
groups, respectively, 𝑃 = 0.50).
3.4. Cytokine Production by Peripheral Blood Mononuclear
Cells. Five days after vaccination with BCG or placebo but
before LPS administration in vivo, there were no differences
between groups in ex vivo cytokine responses induced by spe-
cific (Mycobacterium tuberculosis) or unrelated (LPS, Staphy-
lococcus aureus, and Candida albicans) pathogens or stimuli
(fold change data (compared with baseline) of IFN-𝛾, TNF-𝛼,
and IL-1𝛽 are depicted in Figure 4, and fold change data of IL-
6 and IL-10 are in Supplementary Figure 2. Absolute values
of all cytokines are depicted in Supplementary Figure 3).
Similar to previous endotoxemia experiments [24, 29], four
hours after LPS administration, an overall profound decrease
in ex vivo cytokine production was observed, indicative of
immunoparalysis. BCG vaccination did not influence the
development ormagnitude of immunoparalysis. Likewise, no
differences between groups in ex vivo cytokine responses to
any of the pathogens or stimuli were found on days 8–10 and
25–35 after vaccination. Of note, LPS-induced production
of IFN-𝛾, as well as LPS- and Mycobacterium tuberculosis-
induced production of IL-10, was absent in many subjects
and very low in others. Therefore, the endotoxemia-induced
decrease in ex vivo cytokine production was less noticeable
and did not always reach statistical significance for these
combinations. Staphylococcus aureus- and Candida albicans-
induced IL-10 production was absent in virtually all subjects
and was therefore not analyzed.
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Figure 4: Production of IFN-gamma, TNF-𝛼, and IL-1𝛽 by peripheral blood mononuclear cells stimulated ex vivo with Mycobacterium
tuberculosis (MTB), LPS, Staphylococcus aureus (SA), and Candida albicans (CA) of subjects vaccinated with gamma-irradiated BCG or
placebo. Data expressed as median and interquartile range of the fold change compared with day 1 (before vaccination) (𝑛 = 10 per group). 𝑃
values calculated using repeated measures two-way analysis of variance (ANOVA, time and interaction terms) on log-transformed data. Day
6 was the endotoxemia experiment day.
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4. Discussion
In the present study, we demonstrate that gamma-irradiated
BCG vaccination does not influence the LPS-induced innate
immune response in adult males in vivo five days later.
Furthermore, no effects of BCG vaccination on cytokine
production of leukocytes stimulated ex vivowith specific and
unrelated pathogens were observed.
As all measured parameters were similar between groups,
we can conclude that five days after vaccination gamma-
irradiated BCG has no effect on the innate immune system
and therefore does not induce trained immunity. This is evi-
dent from both the lack of an effect on LPS-induced plasma
cytokine levels in vivo and similar ex vivo innate cytokine
responses (TNF-𝛼, IL-1𝛽, IL-6, and IL-10) against unrelated
pathogens five days after vaccination in both groups. Previous
epidemiological studies have shown that scar formation after
vaccinia or BCG vaccination is associated with improved
survival, possibly related to improved resistance against
infections [27, 28]. Therefore, we stratified subjects based
on scar size, but no effects were found in these analyses
either. Furthermore, no effects indicative of trained immunity
induction were found at later time points, ranging from 8–10
days to 25–35 days after vaccination.
Our results are different from previous studies that used
the live attenuated BCG vaccine [17, 21] instead of the
gamma-irradiated BCG. There are several reasons and/or
limitations of the present study that might explain these
differences. First and foremost, we used gamma-irradiated
BCG in the present study because our target treatment
population consists of immunoparalyzed septic patients who
may be at risk for disseminated mycobacterial infection
[22]. We hypothesized that gamma-irradiated BCG would
be effective in inducing trained immunity in vivo because
recent unpublished data of our group showed that gamma-
irradiated BCG exerts monocyte training in vitro. Further-
more, previous in vitro studies showed that monocytes could
be trained with live BCG, as well as with the inert NOD2
ligand MDP [17], highlighting that live BCG persistence
is not mandatory for inducing trained immunity in vitro.
Nevertheless, inactivating the vaccine could have reduced
or abrogated the “training capacity” of BCG. While live
vaccines can replicate and/or disseminate in the host’s body
and thereby trigger the immune response to a greater extent,
inactivated vaccines only activate immune responses locally
[30]. Although the scar formation in gamma-irradiatedBCG-
vaccinated subjects indicates a local immune response, it
could be envisioned that possible training effects of gamma-
irradiated BCG are much less sustained and widespread and
thus less pronounced. Along these lines, it was demonstrated
that two and four weeks after vaccination with live BCG,
83 and 50% of individuals still displayed viable BCG at the
vaccination site [31], respectively, indicative of a relatively
long-lasting “active infectious pool” of bacteria (or their
products) and/or cytokines that trigger a variety of responses.
This is likely not relevant for the in vitro situation, where cells
are continuously exposed to bacteria and/or their products
irrespective of whether they are alive or inactivated. Also,
others have shown that viable bacteria elicit more potent
immune responses compared to killed bacteria, due to recog-
nition of so-called “vita-PAMPs” such as prokaryotic mRNA
by innate immune cells [32]. The absent effects of gamma-
irradiated BCG on ex vivo cytokine responses to stimulation
with M. tuberculosis further substantiate the hypothesis that
gamma-irradiation results in functional inactivation of BCG,
resulting in abrogation not only of trained immunity but also
of “classic” specific protection againstM. tuberculosis.
Secondly, the timing of the interventions in our study
might have precluded effects of gamma-irradiated BCG. We
chose to assess in vivo and ex vivo responses already five
days after vaccination, in order to assess potential short-
term effects that may be most relevant during sepsis. We
hypothesized that this period would be sufficient to induce
trained immunity based on the fact that in vitro training by
BCGonly takes one day and that nonspecific beneficial effects
of BCG vaccination in neonates were already apparent within
3 days [15]. Nevertheless, in previous studies enhancing
effects of BCG on leukocytes were found 2 weeks, 3 months,
and one year after vaccination [17, 21]. No earlier time points
were assessed in these earlier studies.
Thirdly, we only included young male volunteers in this
study. There are considerable differences in the cytokine
response to LPS betweenmales and females [33].This is likely
influenced by menstrual cycle-related hormonal variations
that can affect the immune response. Because we wanted
our study population to be as homogenous as possible, we
therefore included only males, analogous to virtually all of
our previous endotoxemia studies. This might have biased
our results, because themajority of the studies on nonspecific
effect of the BCG vaccine point to important sex-differential
nonspecific effects and often the most pronounced effects
were observed among females [12, 34, 35]. Nonspecific effects
may also vary with age; nevertheless, live BCG exerted
profound effects in a similarly aged study population [17, 21].
Fourthly, possible training effects of gamma-irradiated
BCG on monocytes in the long term might have been
obscured by the LPS administration five days after vaccina-
tion. BCG-induced trained immunity has been shown to be
mediated through epigenetic reprogramming of monocytes
[17]. Interestingly, exposure to LPS results in opposite epige-
netic changes inmonocytes and/ormacrophages [20].There-
fore, possible training effects induced by gamma-irradiated
BCG might have been nullified by the LPS administration.
Fifthly, the human endotoxemia model employed in this
study is relatively mild and does not replicate the severe
sepsis-induced immunoparalysis observed in actual patients.
Therefore, we cannot exclude the possibility that gamma-
irradiated BCG exerts immunomodulatory effects in a true
model of immunoparalysis or in immunoparalyzed septic
patients, although this appears unlikely based on the com-
plete absence of effects in the present study.
Finally, our study is limited by the fact that, apart from
medical history, we did not screen our subjects for previous
exposure to Mycobacterium tuberculosis. We chose not to
perform a tuberculin skin test since this could trigger trained
immunity effects on its ownwhichwould confound our study
results. However, the infectious pressure of tuberculosis in
10 Journal of Immunology Research
Netherlands is very low [36], and this possibility is unlikely
to explain the absent effects of gamma-irradiated BCG.
In view of the points raised above, a study using live
BCG and possibly other timing of the interventions could
be considered. While such a study would be warranted to
elucidate the mechanisms behind the important nonspecific
beneficial effects of BCG vaccination in neonates [9–15], it
may be less relevant with regard to sepsis patients, in which
the use of live BCG vaccine would be associated with too high
risks.
5. Conclusions
Gamma-irradiated BCG does not modulate the in vivo
innate immune response in adult male volunteers five days
after vaccination. Furthermore, vaccination did not induce
trained immunity ex vivo. Therefore, gamma-irradiated
BCG is unlikely to represent a viable treatment option to
restore immunocompetence in patients with sepsis-induced
immunoparalysis.
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